Marijuana company Cronos Group Inc. announced this week that it has entered into a sponsored research agreement with the Technion Research and Development Foundation of the Technion – Israel Institute of Technology.
As part of the agreement, they will explore the use of cannabinoids and their role in regulating skin health and skin disorders with a focus on three skin conditions: acne, psoriasis and skin repair.
Preclinical studies will be conducted by Technion over a three-year period and research will be led by Technion faculty members Dr. David Meiri, who is the Head of Laboratory of Cancer Biology and Cannabinoid Research and Dr. Yaron Fuchs, the Head of Laboratory of Cancer Biology and Cannabinoid Research. Both are regarded as two of the world’s leading researchers in cannabis and skin stem cell research.
“We believe that the potential applications of cannabinoids to regulate skin health and treat skin disorders are vast, and we are excited to begin exploring these applications through our partnership with Technion,” said Cronos Group CEO Mike Gorenstein.
“Using rigorous data to develop efficacious topical and transdermal formulations will be key to creating differentiated products that provide quality treatments to our consumers and strengthen our brand portfolio.”
“We are pleased to partner with Cronos Group on this groundbreaking cannabinoid research,” said Dr. Fuchs. “Using our state of the art technology, we hope to unlock the vast therapeutic potential of cannabinoid formulations for treating skin disorders.”
“We are thrilled to begin this joint research with Dr. Meiri and Dr. Fuchs, who are among the most respected researchers in their fields,” remarked David Hsu, COO of Cronos.
“Dr. Meiri’s extensive cannabis strain database and capabilities in analytical testing provide a strong foundation for researching Dr. Fuch’s world renowned stem cell organoids. Dr. Meiri and Dr. Fuchs’ expertise coupled with Cronos Group’s competencies in the cannabis industry make us optimistic about the future opportunities from this collaboration,” Hsu added.
Disclaimer: We have no position in Cronos Group Inc. (NASDAQ: CRON) and have not been compensated for this article.
